UroGen has completed enrollment in its Phase 3 clinical trial of UGN-102 in the development of low-to-intermediate-risk, non-muscle-invasive bladder cancer (LG-IR-NMIBC). | Jobs Vox
[ad_1] –If approved, UGN-102 would be the first non-surgical first-line treatment for highly relapsing, multi-resectable bladder cancer. PRINCETON, NJ–( BUSINESS WIRE )– UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing and commercializing innovative solutions for the treatment of urologic and specialty cancers, announced the Phase 3 ENVISION study of UGN. 102 (mitomycin), … Read moreUroGen has completed enrollment in its Phase 3 clinical trial of UGN-102 in the development of low-to-intermediate-risk, non-muscle-invasive bladder cancer (LG-IR-NMIBC).
| Jobs Vox